Provided by Tiger Trade Technology Pte. Ltd.

Pliant Therapeutics, Inc.

1.04
-0.0150-1.43%
Post-market: 1.040.00000.00%19:30 EDT
Volume:402.81K
Turnover:418.71K
Market Cap:64.08M
PE:-0.69
High:1.07
Open:1.06
Low:1.03
Close:1.05
52wk High:1.95
52wk Low:1.02
Shares:61.91M
Float Shares:55.03M
Volume Ratio:1.23
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5000
EPS(LYR):-2.4336
ROE:-50.29%
ROA:-23.27%
PB:0.44
PE(LYR):-0.43

Loading ...

Pliant Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer David Raben

Reuters
·
Yesterday

PLRX’s FORTIFY Trial: Early Oncology Bet With Upside for Immune-Oncology Investors

TIPRANKS
·
Yesterday

Pliant Therapeutics Appoints David Raben, M.d., as Chief Medical Officer

THOMSON REUTERS
·
Oct 01

Pliant Rises After FDA Grants Fast-Track Tag to Experimental Cancer Drug

Reuters
·
Aug 18

Pliant Wins FDA Fast Track Status for PLN-101095 Plus Keytruda in ICI-Refractory Solid Tumors

Reuters
·
Aug 18

Pliant Therapeutics Receives FDA Fast Track Designation for Pln-101095 in Combination with Pembrolizumab for the Treatment of Ici-Refractory Solid Tumors

THOMSON REUTERS
·
Aug 18

Pliant Therapeutics, - Pln-101095 Data from Phase 1a/1B Fortify Trial Expected in 2027

THOMSON REUTERS
·
Aug 18

Outlook Therapeutics Q3 Net Loss Narrows Slightly as Costs Drop

Reuters
·
Aug 14

Grace Therapeutics Q1 Net Loss Widens on Impairment Charges

Reuters
·
Aug 13

Indaptus Q2 Net Loss Narrows as Costs Fall

Reuters
·
Aug 13

Oppenheimer Sticks to Their Hold Rating for Pliant Therapeutics (PLRX)

TIPRANKS
·
Aug 13

Atara Biotherapeutics Q2 Revenue Falls on Deferred Revenue Recognition

Reuters
·
Aug 13

Humacyte Q2 Net Loss Widens on Inventory, Production Costs

Reuters
·
Aug 12

RBC Capital Sticks to Their Hold Rating for Pliant Therapeutics (PLRX)

TIPRANKS
·
Aug 12

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tecan Group AG (OtherTCHBF), Kyverna Therapeutics, Inc. (KYTX) and Pliant Therapeutics (PLRX)

TIPRANKS
·
Aug 12

Aardvark Therapeutics Q2 Operating Expenses Fall on Paused ARD-101 Clinical Trials and Workforce Reduction

Reuters
·
Aug 12

Pliant Therapeutics Q2 Net Income USD -22.371 Million

Reuters
·
Aug 12

Pliant Therapeutics Q2 Net Loss Narrows on Operating Expenses Decline, Reduced Headcount

Reuters
·
Aug 12

Pliant Therapeutics Catat Rugi Bersih Q2 FY26 Menyempit Ke $ 22,37 Juta; Biaya R&D Turun 48,05% Ke $ 16,73 Juta

Reuters
·
Aug 12

Pliant Therapeutics Q2 Operating Income USD -23.862 Million

THOMSON REUTERS
·
Aug 12